✦ LIBER ✦

Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594 : A Phase III trial in patients with metastatic nonsmall cell lung carcinoma

✍ Scribed by Christopher J. Sweeney; Junming Zhu; Alan B. Sandler; Joan Schiller; Chandra P. Belani; Corey Langer; James Krook; David Harrington; David H. Johnson

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 107 KB
Volume: 92
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20011115)92:10<2639::aid-cncr1617>3.0.co;2-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized Phase II trial of echinomyc

A randomized Phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma : An Eastern Cooperative Oncology Group Study (E1587)

✍ Alex Y. Chang; KyungMann Kim; Hélène Boucher; Philip Bonomi; James A. Stewart; D 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

## Background: Patients with metastatic nonsmall cell lung carcinoma (nsclc) usually have a poor prognosis. a chemotherapy regimen containing cisplatin is commonly used for symptom palliation. echinomycin is a potent bifunctional intercalator of double-strand dna; trimetrexate is a new derivative o

Phase I trial of docetaxel and vinorelbi

Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma

✍ Vincent A. Miller; Kenneth K. Ng; Lee M. Krug; Wendy Perez; Barbara Pizzo; Rober 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

## Background: With preclinical evidence of synergy, this dose-finding trial examining the combination of docetaxel and vinorelbine given with prophylactic filgrastim for the treatment of patients with nonsmall cell lung carcinoma was undertaken. ## Methods: Twenty-seven patients with advanced no

A Phase II study of all-trans-retinoic a

A Phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma : An Eastern Cooperative Oncology Group study

✍ Gregory P. Kalemkerian; Michael Jiroutek; David S. Ettinger; John A. Dorighi; Da 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 1 views

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

A phase II study of 5-fluorouracil, leuc

A phase II study of 5-fluorouracil, leucovorin, and interferon-α in the treatment of patients with metastatic or recurrent gastric carcinoma : An Eastern Cooperative Oncology Group study (E5292)

✍ Gary R. Hudes; Stuart Lipsitz; Jean Grem; Mary Morrisey; Louis Weiner; John W. K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

Chemotherapy has a limited impact on adenocarcinoma of the stomach. Although biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (LV) and interferon-␣ (IFN-␣) has improved the outcomes of patients with metastatic colorectal carcinoma compared with 5-FU alone, this approach has not been ext

A phase II trial of interferon-α and 5-f

A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study

✍ Laurence Elias; Brent A. Blumenstein; Julie Kish; Robert C. Flanigan; James L. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 1 views

## BACKGROUND. Renal cell carcinoma is a common neoplasm that is often refractory to treatment. It is occasionally responsive to immunoniodulating agents including interferon-a, which enhances the effects of 5-fluorouracil upon cells. Combinations of these two drugs have been most frequently tested

Final report of a phase II evaluation of

Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck : An Eastern Cooperative Oncology Group trial (PA390)

✍ Arlene A. Forastiere; Darleen Shank; Donna Neuberg; Samuel G. Taylor IV; Ronald 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.